Resource Logo
AIDS Weekly Plus

AIDS Therapies: Blood Protein Found to Halt Replication of HIV


-- Researchers at the University of Colorado Health Sciences Center have shown in laboratory studies that a molecule found in the human body can halt the growth of HIV.

In a paper accepted for publication in the January 1, 2001, issue of the Federation of the American Societies of Experimental Biology Journal (FASEB), the researchers describe various ways in which alpha-1 antitrypsin (AAT), a naturally-occurring protein in blood, prevents HIV from reproducing and from being spread to healthy cells. The AAT used in these investigations was purified from the blood of healthy volunteers who donated blood for research to the American Red Cross.

This novel path in AIDS research was led by Leland Shapiro, MD, assistant professor of medicine at CU-Health Sciences Center and principal investigator of the study. Several observations led the research team to search for a potent natural HIV inhibitor in blood.

"In the laboratory, we confirmed the surprising observation that the AIDS virus did not grow in blood," Shapiro said. "This suggested that there was at least one substance in the blood that blocked the virus. We believe we have identified one of the substances as AAT, the most abundant inhibitor of serine proteases in the blood."

The laboratory results were dramatic. Shapiro observed that although HIV did not proliferate when added to blood obtained from healthy volunteers, the virus replicated readily when added to blood from patients who had reduced AAT due to a genetic defect.

In other studies, the team found that in special cells designed to detect infection with HIV, AAT blocked the ability of the virus to infect previously healthy, uninfected cells. The research team next studied cells chronically infected with HIV. These cells can be induced by a variety of stimuli to produce high levels of HIV. When these cells were stimulated in the presence of AAT, however, viral production was reduced by 90% to 100% compared to cells without AAT present.

This effect was observed regardless of the stimulus used to increase virus production in the cells. AAT also was able to stop HIV replication in natural, freshly infected blood mononuclear cells, a type of blood cell involved in fighting infections and healing wounds.

Shapiro and the research team propose that although AAT exists normally in the body, HIV appears to reproduce in areas where the amounts of AAT are low, such as in the lymph glands. By injecting infected patients with AAT it might be possible to increase AAT at the sites of viral replication. This might bolster the defense against the virus by preventing the production of HIV from infected cells and blocking the spread of virus to healthy cells.

The research group also described experiments using a synthetic inhibitor of host serine proteases developed by Cortech to function as an AAT "mimic." This synthetic "mimic" possessed nearly identical effects as naturally-occurring AAT in inhibiting HIV. This suggests to the researchers that a pill eventually might be designed to treat AIDS.

"These findings are preliminary but promising," Shapiro said. "Inhibitors of serine proteases should be considered as candidates for treating the AIDS virus. If clinical results are as promising as what we have seen in the laboratory, methods of increasing AAT or use of an AAT 'mimic' might be an effective form of AIDS therapy."

He adds that the results of this research suggest that this approach to treatment may work regardless of viral mutations.

Clinical trials will be proposed to the AIDS Clinical Trials Group, which is based at the CU-Health Sciences Center. Additional laboratory studies and clinical studies in human subjects are required to determine the effectiveness of serine protease inhibitors like AAT or the AAT "mimic" in battling AIDS.

Christopher C. Lamb, CEO of the American Red Cross Plasma Services, found the research results interesting. "The American Red Cross is pleased to have the opportunity to support such exciting and innovative research," he said.

This article was prepared by AIDS Weekly editors from staff and other reports.


Copyright © 2000 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.

Information in this article was accurate in December 25, 2000. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.